memantine and Addiction, Opioid studies

Research Excerpts

Excerpt	Relevance	Reference
"The memantine 30mg group was significantly less likely to relapse and to use opioids after buprenorphine discontinuation."	2.80	Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. ( DiGirolamo, G; Gonzalez, G; Kolodziej, M; Romero-Gonzalez, M; Smelson, D; Ziedonis, D, 2015)
"Demand for treatments for severe opioid use disorder is increasing worldwide."	2.66	Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. ( Fluyau, D; Pierre, CG; Revadigar, N, 2020)
"Memantine was well tolerated with similar rates of adverse effects between treatment groups."	2.61	Adjunctive memantine for opioid use disorder treatment: A systematic review. ( Brown, JN; Elias, AM; Pepin, MJ, 2019)
"Trichostatin A was also observed to exert a synergistic interaction with Ac-DEVD-CHO."	1.38	Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. ( Rachamalla, M; Rehni, AK; Singh, N; Tikoo, K, 2012)

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Opiate Craving Based on Heroin Craving Scale

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (20.00)	29.6817
2010's	7 (70.00)	24.3611
2020's	1 (10.00)	2.80

Authors	Studies
Elias, AM	1
Pepin, MJ	1
Brown, JN	1
Fluyau, D	1
Revadigar, N	1
Pierre, CG	1
Romero-Gonzalez, M	2
Shahanaghi, A	1
DiGirolamo, GJ	1
Gonzalez, G	2
Lee, SY	2
Chen, SL	2
Chang, YH	2
Chen, PS	2
Huang, SY	1
Tzeng, NS	1
Wang, LJ	1
Lee, IH	2
Wang, TY	2
Chen, KC	2
Yang, YK	2
Hong, JS	2
Lu, RB	2
DiGirolamo, G	1
Smelson, D	1
Ziedonis, D	1
Kolodziej, M	1
Bisaga, A	2
Sullivan, MA	1
Cheng, WY	1
Carpenter, KM	1
Mariani, JJ	1
Levin, FR	1
Raby, WN	1
Nunes, EV	1
Rehni, AK	1
Singh, N	1
Rachamalla, M	1
Tikoo, K	1
Mendez, IA	1
Trujillo, KA	1
Comer, SD	1
Ward, AS	1
Popik, P	1
Kleber, HD	1
Fischman, MW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence[NCT00476242]	Phase 2/Phase 3	82 participants (Actual)	Interventional	2008-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Range 0- 100 ( 0= no craving; 100= very strong craving (NCT00476242)
Timeframe: Average of twice weekly assessments for 12 weeks of study or length of participation

Opiate Use Measured by Urine Toxicology Results

Intervention	units on a scale (Mean)
Placebo and Vivitrol	18.47
Memantine and Vivitrol	15.74

Opiate use was qualified by the number of opiate positive urine results. (NCT00476242)
Timeframe: 3x/week during 12 weeks of the trial or study participation

Article	Year
Adjunctive memantine for opioid use disorder treatment: A systematic review. Journal of substance abuse treatment, 2019, Volume: 107 Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Hum	2019
Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. Drug and alcohol dependence, 2020, 03-01, Volume: 208 Topics: Analgesics, Opioid; Excitatory Amino Acid Antagonists; Humans; Ketamine; Memantine; Methadone; Opiat	2020

Article	Year
Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial. Scientific reports, 2015, May-19, Volume: 5 Topics: Analgesics, Opioid; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Dopamine Agents; Double-B	2015
Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. Drug and alcohol dependence, 2015, Nov-01, Volume: 156 Topics: Adolescent; Adult; Buprenorphine, Naloxone Drug Combination; Dose-Response Relationship, Drug; Doubl	2015
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug and alcohol dependence, 2011, Dec-01, Volume: 119, Issue:1-2 Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication A	2011
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology, 2001, Volume: 157, Issue:1 Topics: Adult; Dextromethorphan; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Morphin	2001

Article	Year
Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders. The American journal on addictions, 2017, Volume: 26, Issue:8 Topics: Adolescent; Age Factors; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cognitive Beh	2017
Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy. Scientific reports, 2015, May-19, Volume: 5 Topics: Cognition; Drug Monitoring; Female; Follow-Up Studies; Humans; Male; Memantine; Opiate Substitution	2015
Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:6 Topics: Analgesics, Opioid; Animals; Behavior, Animal; Brain; Cysteine Proteinase Inhibitors; Female; Histon	2012
NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology, 2008, Volume: 196, Issue:3 Topics: Animals; Behavior, Animal; Buprenorphine; Dizocilpine Maleate; Drug Tolerance; Excitatory Amino Acid	2008

memantine and Addiction, Opioid

Research Excerpts

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Opiate Craving Based on Heroin Craving Scale

Opiate Use Measured by Urine Toxicology Results

Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).

Reviews

Trials

Other Studies